All news

Pfizer (PFE) Scores Legal And Product Wins, Is The Stock Now Too Expensive?

Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash

Pfizer recently secured a legal victory in Europe regarding a Paxlovid-related patent and has seen its stock price rise significantly this year, up 21.2% year to date. Despite these wins and a strong pipeline of non-COVID therapies, Simply Wall St suggests Pfizer may be overvalued by 5.7%, with its shares trading at $30.52 against a fair value of $28.88.

Read original source

PFE company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.